Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/1/1999 First Published: 4/1/1999


1.		Phase III Study of IDEC-Y2B8 in Patients With Progressive Follicular B-Cell Non-Hodgkin's Lymphoma That is Refractory to Prior Rituximab Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				IDEC-106-06 MAYO-987804, UCLA-9808026

Last Modified: 1/1/2000 First Published: 11/1/1999


2.		Phase II Study of Ibritumomab Tiuxetan (IDEC-Y2B8) Radioimmunotherapy in Patients with Relapsed or Refractory, Low Grade or B-Cell, Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-9804024 IDEC-106-05, NCI-G99-1614

Last Modified: 6/1/2002 First Published: 5/1/2000


3.		Phase II Study of Rituximab and Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Relapsed or Refractory, Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UAB-9930 GUMC-00095, IDEC-106-98, NCI-G00-1731, NCT00005592

Last Modified: 10/23/2008 First Published: 3/24/2003


4.		Phase II Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Patients Age 60 and Over With Previously Untreated Diffuse Large B-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Closed				60 and over				NCI				MSKCC-02090 NCT00058422

Last Modified: 9/25/2007 First Published: 5/1/2002


5.		Phase I Study of Rituximab Followed By Yttrium Y 90 Ibritumomab Tiuxetan With or Without Autologous Peripheral Blood Stem Cell Transplantation in Children With Recurrent or Refractory CD20-Positive Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				Under 22				NCI				COG-ADVL0013 NCT00036855, ADVL0013

Last Modified: 10/30/2007 First Published: 2/16/2007


6.		Phase I Study of CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With CD20+ Recurrent or Refractory Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Diagnostic, Treatment				Closed				18 and over				NCI				MAYO-LS0382 MAYO-IRB-703-04, NCT00438880

Select All on One Page